



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,237	07/24/2001	Sean E. Egan	3477-89	4932

20792 7590 10/02/2002
MYERS BIGEL SIBLEY & SAJOVEC
PO BOX 37428
RALEIGH, NC 27627

EXAMINER

CAPUTA, ANTHONY C

ART UNIT	PAPER NUMBER
1642	

DATE MAILED: 10/02/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/674,237

Applicant(s)

EGAN ET AL.

Examiner

Brenda G. Brumback

Art Unit

1642

*-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --***Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on _____.
2a) This action is **FINAL**. 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-58 is/are pending in the application.
4a) Of the above claim(s) ____ is/are withdrawn from consideration.
5) Claim(s) ____ is/are allowed.
6) Claim(s) ____ is/are rejected.
7) Claim(s) ____ is/are objected to.
8) Claim(s) 1-58 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). _____.
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 6) Other: _____.

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 2, 4, 5, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:3 encoding a murine Esc1 and a process of recombinantly producing murine Esc1, classified in class 536, subclass 23.5.
- II. Claims 1, 2, 4, 5, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:24 encoding a murine Esc1 and a process of recombinantly producing murine Esc1 , classified in class 536, subclass 23.5.
- III. Claim 1, 2, 4, 19 (in part) and 3, drawn to an isolated nucleic acid comprising a nucleotide sequence encoding a human Esc1, and a process of recombinantly producing human Esc1 classified in class 536, subclass 23.5.
- IV. Claims 1, 2, 4, 6-10, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:1 encoding a murine Esc1 and a process of recombinantly producing murine Esc1 , classified in class 536, subclass 23.5.
- V. Claims 1, 2, 4, 6-10, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:2 encoding a murine Esc1 and a process of recombinantly producing murine Esc1, classified in class 536, subclass 23.5.
- VI. Claims 1, 2, 4, 6-10, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:22 encoding a murine Esc1 and a process of recombinantly producing murine Esc1 , classified in class 536, subclass 23.5.

Art Unit: 1642

- VII. Claims 1, 2, 4, 6-10, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:23 encoding a murine Esc1 and a process of recombinantly producing murine Esc1, classified in class 536, subclass 23.5.
- VIII. Claim 1, 2, 4, 6-10, and 19 (in part), drawn to an isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO:23 encoding a murine Esc1 and a process of recombinantly producing murine Esc1, classified in class 536, subclass 23.5.
- IX. Claim 11, 12, and 14-17 (in part), drawn to a pure murine Ese1 or Ese1L protein of SEQ ID NO:3, classified in class 530, subclass 350.
- X. Claim 11 (in part) and 13, drawn to a pure human Ese1 or Ese1L protein, classified in class 530, subclass 350.
- XI. Claim 11, 12, and 14-17 (in part), drawn to a pure murine Ese1 or Ese1L protein of SEQ ID NO:24, classified in class 530, subclass 350.
- XII. Claim 18 (in part), drawn to an antibody which binds a pure murine Ese1 or Ese1L protein of SEQ ID NO:3, classified in class 530, subclass 350.
- XIII. Claim 18 (in part), drawn to an antibody which binds a pure murine Ese1 or Ese1L protein of SEQ ID NO:24, classified in class 530, subclass 350.
- XIV. Claims 20-21, 23, 24, and 38 (in part), drawn to an isolated nucleic acid encoding a murine Ese2 protein of SEQ ID NO:6, classified in class 536, subclass 23.5
- XV. Claims 20, 22, 23 and, 38 (in part), drawn to an isolated nucleic acid encoding a human Ese2 protein.
- XVI. Claims 20-21, 23, 24, and 38 (in part), drawn to an isolated nucleic acid encoding a murine Ese2 protein of SEQ ID NO:27, classified in class 536, subclass 23.5
- XVII. Claims 20-21, 23, and 24-29, 38 (in part), drawn to an isolated nucleic acid of SEQ ID NO: 4 encoding a murine Ese2 protein, classified in class 536, subclass 23.5

Art Unit: 1642

XVIII. Claims 20-21, 23, 24-29, and 38 (in part), drawn to an isolated nucleic acid of SEQ ID NO: 5 encoding a murine Ese2 protein, classified in class 536, subclass 23.5

XIX. Claims 20-21, 23, 24-29, and 38 (in part), drawn to an isolated nucleic acid of SEQ ID NO: 25 encoding a murine Ese2 protein, classified in class 536, subclass 23.5.

XX. Claims 20-21, 23, 24-29, and 38 (in part), drawn to an isolated nucleic acid of SEQ ID NO: 26 encoding a murine Ese2 protein, classified in class 536, subclass 23.5

XXI. Claims 30, 31, and 33-36 (in part) drawn to a murine Ese2 or Ese21 protein of SEQ ID NO: 6 classified in class 530, subclass 350.

XXII. Claims 30 and 36 (in part) and 32, drawn to a human Ese2 or Ese21 protein, classified in class 530, subclass 350.

XXIII. Claims 30, 31, and 33-36 (in part) drawn to a murine Ese2 or Ese21 protein of SEQ ID NO: 27 classified in class 530, subclass 350.

XXIV. Claim 37 (in part), drawn to an antibody which specifically binds a murine Ese2 or Ese21 protein of SEQ ID NO: 6 classified in class 530, subclass 387.1.

XXV. Claim 37 (in part), drawn to an antibody which specifically binds a murine Ese2 or Ese21 protein of SEQ ID NO: 27 classified in class 530, subclass 387.1.

XXVI. Claim 37 (in part), drawn to an antibody which specifically binds a humane Ese2 or Ese21 protein, classified in class 530, subclass 387.1.

XXVII. Claim 39 drawn to a pharmaceutical composition comprising an Ese protein, classified in class 514, subclass 12.

XXVIII. Claims 40, 43 drawn to a method of screening a candidate compound, classified in class 435, subclass 7.1

Art Unit: 1642

XXIX. Claims 41-45 and 47, drawn to a method of treating or preventing a disorder characterized by an abnormality in the endocytic pathway, classified in class 424, subclass 130.1, for example.

XXX. Claim 46, drawn to a method of preventing viral infection in a mammal, classified in class 424, subclass 130.1, for example.

XXXI. Claims 48-49, drawn to methods of regulating endocytosis in cultured cells, classified in class 435, subclass 325, for example.

Inventions IX-XIII and XXI-XXVI and XXVIII-XXXI are related as products and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides and antibodies of Inventions IX-XIII and XXI-XXVI can be used in the materially different processes of affinity purification of antibodies and antigens.

The products of Inventions I-XXVII have different structures, different chemical compositions, and different immunological properties.

The methods of Inventions XXVIII-XXXI utilize different components, have different method steps, are for different purposes and have different outcomes.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Art Unit: 1642

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda Brumback whose telephone number is (703) 306-3220. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be marked "OFFICIAL" for entry into prosecution history or "DRAFT" for consideration by the examiner without entry. The Official FAX telephone number is (703) 872-9306 and the After Final FAX telephone number is (703) 872-9307. FAX machines will be available to receive transmissions 24 hours a day. In compliance with 1096 OG 30, the filing date accorded to each OFFICIAL fax transmission will be determined by the FAX machine's stamped date found on the last page of the transmission, unless that date is a Saturday, Sunday or Federal Holiday with the District of Columbia, in which case the OFFICIAL date of receipt will be the next business day.

BB

October 1, 2002


Brenda Brumback
Supervisory Patent Examiner
Technology Center 1600